Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
With 73% Ownership of the Shares, Johnson & Johnson (NYSE:JNJ) Is Heavily Dominated by Institutional Owners
Express News | Pharma Mar - Reaches Commercial Milestone About Yondelis (Trabectedin) in United States
Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Alvotech, Advanz's Application for AVT05 Accepted by European Medicines Agency
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
Express News | The results of the national medical insurance negotiations are expected to be released at the end of November 2024.
Stocks That Hedge Funds Moved From Long to Short in August - Jefferies
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
AbbVie Lifts Outlook Again on Immunology Demand; Dividend Raised
Johnson & Johnson (JNJ.US) monoclonal antibody therapy announced positive Phase 3 data, achieving significant clinical remission and endoscopic response.
johnson & johnson (JNJ.US) recently announced the positive results of its white blood cell interleukin-23 (IL-23) targeted antibody Tremfya (guselkumab) in the GRAVITI phase 3 clinical trial.
Direct hit on the usa election | Trump VS Harris, how should investors deal with the election market?
The current market generally believes that, given Trump's current stance, he supports traditional energy, infrastructure construction policies; while if Harris takes office, she tends to welfare policies, marijuana legalization, green energy, USA export growth, housing support, etc. It is worth noting that market views believe that whether it is Trump or Harris taking office, it is bullish for cryptos and gold.
Grifols's Fibrin Sealant Approved by FDA for Children; Shares Rise
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Express News | Shockwave Medical Completes Enrollment in All-Female Coronary Ivl Study
Express News | J&J -European Commission Approves Expanded Use of Hiv-1 Therapy Edurant® (Rilpivirine) in Younger Pediatric Patients
DOJ Throws Wrench Into J&J Bankruptcy Plan to Settle Talc Suits
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update
J&J Impella ECP Heart Pump Meets Primary Endpoint